LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.

Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B

Diabetes, obesity & metabolism19 Jan 2011Cited by 59 (Europe PMC)

PMID21251179DOI10.1111/j.1463-1326.2011.01365.xPepBankPUB-21251179

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialSafety outcome
In healthy subjects, LY was generally well tolerated.
In plain wordsIn healthy subjects, LY was generally well tolerated.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.1-12 mg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
LY was generally well tolerated with some increase in gastrointestinal symptoms with escalating doses.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117901
02HumanRandomized controlled trialSafety outcome
In healthy subjects, gastrointestinal symptoms increased somewhat with escalating LY doses.
In plain wordsIn healthy subjects, stomach and bowel symptoms increased somewhat as LY doses increased.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGastrointestinal symptoms
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.1-12 mg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
LY was generally well tolerated with some increase in gastrointestinal symptoms with escalating doses.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117902
03HumanRandomized controlled trialSafety outcome
In healthy subjects, LY doses ≥1.0 mg produced small dose-dependent pulse rate increases.
In plain wordsIn healthy subjects, LY doses ≥1.0 mg caused small increases in pulse rate that depended on dose.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreasePulse rate
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Studied dose
>=1.0 mg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
There were small dose-dependent increases in pulse rate with doses ≥1.0 mg and diastolic blood pressure with doses ≥3.0 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117903
04HumanRandomized controlled trialSafety outcome
In healthy subjects, LY doses ≥3.0 mg produced small dose-dependent diastolic blood pressure increases.
In plain wordsIn healthy subjects, LY doses ≥3.0 mg caused small increases in the lower blood pressure reading.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDiastolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
>=3.0 mg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
There were small dose-dependent increases in pulse rate with doses ≥1.0 mg and diastolic blood pressure with doses ≥3.0 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117904
05HumanRandomized controlled trialPharmacokinetics
In healthy subjects, LY had an approximately 90 h half-life.
In plain wordsIn healthy subjects, LY had an approximately 90 h half-life.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHalf-life
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.1-12 mg · subcutaneous · single doseAs given in this study (human).
Measurements
Half-life
≈ 90 h
LY
Source sentences
Summary
The half-life of LY was approximately 90 h, with C(max) occurring between 24 and 48 h in most subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117905
06HumanRandomized controlled trialPharmacokinetics
In most healthy subjects, LY peak concentration occurred between 24 and 48 h.
In plain wordsIn most healthy subjects, LY reached its highest concentration between 24 and 48 h.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTime to peak concentration
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.1-12 mg · subcutaneous · single doseAs given in this study (human).
Measurements
Time to peak concentration
24 to 48 h
most subjects
Source sentences
Summary
The half-life of LY was approximately 90 h, with C(max) occurring between 24 and 48 h in most subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117906
07HumanRandomized controlled trialMechanism
In healthy subjects, all LY doses increased glucose-dependent insulin secretion during OGTT compared with placebo.
In plain wordsIn healthy subjects, all LY doses increased glucose-dependent insulin release during the glucose test compared with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGlucose-dependent insulin secretion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1-12 mg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Evidence of increase in glucose-dependent insulin secretion and suppression of serum glucose excursions were observed during an OGTT at all doses compared to placebo; no episodes of hypoglycaemia occurred.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117907
08HumanRandomized controlled trialEfficacy outcome
In healthy subjects, all LY doses suppressed serum glucose excursions during OGTT compared with placebo.
In plain wordsIn healthy subjects, all LY doses reduced blood sugar excursions during the glucose test compared with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSerum glucose excursions
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1-12 mg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Evidence of increase in glucose-dependent insulin secretion and suppression of serum glucose excursions were observed during an OGTT at all doses compared to placebo; no episodes of hypoglycaemia occurred.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117908
09HumanRandomized controlled trialSafety outcome
No healthy subjects experienced hypoglycaemia after LY.
In plain wordsNo healthy subjects experienced low blood sugar after LY.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHypoglycaemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.1-12 mg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Evidence of increase in glucose-dependent insulin secretion and suppression of serum glucose excursions were observed during an OGTT at all doses compared to placebo; no episodes of hypoglycaemia occurred.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117909
10HumanRandomized controlled trialSafety outcome
No healthy subjects developed antibodies to LY2189265.
In plain wordsNo healthy subjects developed antibodies to LY2189265.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAntibodies to LY2189265
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
0.1-12 mg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
No subjects developed antibodies to LY2189265.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and potential immunogenicity of single, escalating subcutaneous injections of a once-weekly glucagon-like peptide-1 analogue in healthy subjects.
Summary · context
This phase 1, three-period, crossover, double-blind, placebo-controlled study investigated single, escalating subcutaneous doses of LY2189265 (LY) ranging from 0.1 to 12 mg; approximately six subjects were randomized to each dose.
Report a problemFND-2125117910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT05459285

A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

Sunshine Lake Pharma Co., Ltd.n = 6831 May 2022 to 8 Jul 2022

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 25 Aug 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.